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Acknowledgements
Mother-to-child-transmission (MTCT) rate has
decreased sharply in recent years in most of the sub-
Saharan Africa, however 220,000 children acquired
HIV-1 in 2014. PCR detection of proviral DNA is the
most sensitive method for early infant diagnosis
(EID) of HIV-1 infection. Commercial kits are
available but they have poor sensitivity with
divergent non-B subtypes and high costs (≈30€ per
test) which limit their use in resource-limited
settings. The HIV-1 epidemic in Angola is driven by
highly divergent strains of all group M subtypes,
except B, as well as multiple recombinant forms
(CRFs and URFs) making EID a challenge in this
setting. The aim of this study was to develop and
validate a qualitative, inexpensive and sensitive “in-
house” HIV-1 EID assay on heel prick dried blood
spots (DBS) from infants of the Hospital da Divina
Providência (HDP) in Luanda, Angola and determine
the current HIV-1 MTCT rate in the Angolan PErinatal
HIV Cohort (APEHC).
• The assay is a qualitative nested PCR based on
new primers targeting the integrase (IN) gene of
the most prevalent HIV-1 subtypes and
recombinant forms found in Angola.
• One-hundred DBS from HIV-1-infected adults were
used as positive controls; fifty DBS from HIV-1
seronegative healthy volunteers were used as
negative controls.
• The analytical sensitivity was assessed with: 1)
ACH-2 cells containing a single, integrated HIV-1
subtype B DNA copy per cell; 2) Recombinant
plasmids containing HIV-1 IN (927pb) of subtypes
A-J and CRF02_AG from Angolan and Portuguese
clinical samples; the sequences were subtyped by
Maximum Likelihood (ML) phylogenetic analysis
with MEGA6.
• Plasmids and ACH-2 cells were diluted in HIV
seronegative blood by 5 log10 serial dilutions and
spotted in Whatman® Human ID blood stain cards.
• DNA was extracted from DBS using chelex-100
resin and a fragment of IN (194 pb) was amplified
by nested PCR. CCR5 gene was also amplified as
an internal control.
• The clinical sensitivity was assessed using DBS
from 126 HIV-1-exposed infants enrolled in the
APEHC from HDP. The median age was 1 month
and 50% were girls. Definitive diagnosis of HIV-1
infection was based on serology at month 12.
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Positive controls
(N=100)
Negative 
controls
(N=50)
Total
EID in-house
test
Undetectable 
viral load (<20 
cop/mL)
Viral load of
20-1,000 
cop/mL
Viral load of 
>1,000 
cop/mL
Positive 11 9 6 0 36
Negative 66 7 1 50 124
Total 77 16 7 50 160
% detection 14.3 56.3 85.7 0 -
 The DBS in-house EID assay has a remarkably low
limit of detection with highly divergent viruses of
all subtypes.
 The high clinical sensitivity and specificity makes
its use suitable for complex HIV-1 epidemics for
EID of HIV-1 infection.
 The low (2.4%) HIV-1 MTCT rate within the APEHC
shows the importance of establishing PMTCT
programs and also the high standards of health
care provided at HDP.
 The exceedingly simplicity and low cost per test
suggests that implementation of this assay in
Angola and in other less-resourced countries will
be possible allowing the early treatment of HIV-1-
infected infants.
Limit of detection of the assay is 4 HIV-1 DNA copies (in ACH-2 cells) and 1-10 
copies based on the recombinants plasmids
• MTCT rate in the APEHC was 2.4% between
January 2012 and October 2014.
• This low rate likely reflects the high standard
of care of HIV infected children and mothers at
HDP in Luanda
Isolate Sampling 
date
Country of Origin 
(Province)
Genotype
(IN)
1-09AOHDP110 2009 Angola (Luanda) D
2-09AOHDP157 2009 Angola (Luanda) G
3-09AOHDP237 2009 Angola (Luanda) F1
4-09AOHDP34 2009 Angola (Luanda) C
5-93AOHDC251 1993 Angola (Cabinda) H
6-01PTHDECJN 1998 Portugal (Lisbon) CRF02_AG
7-00PTHDEEBB 2000 Portugal (Lisbon) G
8-93AOHDC249 1993 Angola (Cabinda) A1
9-93AOHDC253 1993 Angola (Cabinda) J
Corresponding author: ntaveira@ff.ul.pt
APEHC infants 
Serological test 
(n=126)
EID in-house test* Positive Negative Total
Positive 3 0 3
Negative 0 123 123
Total 3 123 126
Recombinant reference plasmids represent the complexity of the HIV-1 strains
circulating in Luanda
• Negative results were obtained with all uninfected
children_Specificity 100%   
• Positive PCR results were obtained with all infected
children_ Sensitivity 100%
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Conclusion
Performance of the assay in DBS samples collected from 
HIV-1 infected adult patients
The probability of detecting HIV-1 proviral DNA with our EID test in the 100
seropositive and 50 seronegative samples tested was:
• 0% when the patients were not infected with HIV-1
• 14.3% when the patients had a plasma viral load of <20 copies/mL
• 56.3% when the patients had a plasma viral load of 20-1,000 copies/mL
• 85.7% when the patients had a plasma viral load >1,000 copies/mL
500 copies 100 copies
D |G | F1|C |H |02|G |A1|J |B |
M
P-B3
